Keith Michael Gottesdiener
CIK 1615856 · See Remarks · last filed 2025-09-29
Keith Michael Gottesdiener is a corporate insider who has filed 36 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing, for SEPN, was dated Sep 29, 2025. Across all open-market trades the lifetime net is −$2.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $73.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RYTM price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
#8C
NEW YORK, NY 10021
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SEPN | Director | — | $50.74 | — | $0 | 1 | 2025-09-29 |
| PRME | See Remarks | 2,361,078 | $4.30 | $10.15M | $0 | 8 | 2025-05-12 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Director | 32,830 | $19.00 | $623.8K | $74.9K | 9 | 2023-05-25 |
| RYTM | CEO & President | 558,250 | $113.94 | $63.61M | -$2.48M | 17 | 2020-03-11 |
Recent Filings
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-09-29 | SEPN | Grant (A) | — | $0 | EDGAR |
| 2025-05-12 | PRME | Grant (A) | — | $0 | EDGAR |
| 2025-03-04 | PRME | Grant (A) | — | $0 | EDGAR |
| 2024-12-09 | PRME | Grant (A) | — | $0 | EDGAR |
| 2024-10-10 | PRME | Gift (G) | — | $0 | EDGAR |
| 2024-06-07 | PRME | Gift (G) | — | $0 | EDGAR |
| 2024-02-27 | PRME | Grant (A) | — | $0 | EDGAR |
| 2023-11-14 | PRME | Gift (G) | −12,500 | $0 | EDGAR |
| 2023-11-13 | — | Mixed | −32,830 | -$623.8K | |
| 2023-05-25 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Grant (A) | +8,111 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.